Table 5. DRM presence at RT and predicted drug susceptibility in viruses from LPV/r-exposed patients with resistance data.
| Patients | First LPV/r exposure | Patients with available data at RTa | Patients with DRM at RT; mean DRM [IQR] | Predicted susceptibility (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| to NRTI | to NNRTI | ||||||||||||||
| to NRTI | to NNRTI | 3TC | ABC | AZT | d4T | ddI | FTC | TDF | EFV | ETV | NVP | RPV | |||
| Group 1 (n = 33) | In 1st cART | 8 (24.2%) | 4 (50%);1.7 [1-3] | 3 (37.5%);2 [1-3] | 50 | 50 | 75 | 75 | 50 | 50 | 75 | 62.5 | 50 | 62.5 | 62.5 |
| Group 2 (n = 37) | In 2nd cART | 8 (24.2%) | 4 (50%);2.5 [1.5-3.5] | 3 (37.5%);1.3 [1-2] | 62.5 | 50 | 75 | 75 | 50 | 62.5 | 62.5 | 75 | 75 | 75 | 75 |
| Group 3 (n = 126) | In ≥3rd cART | 32 (25.4%) | 20 (62.5%);4.3 [3-6] | 15 (46.9%);2.3 [1-3] | 43.7 | 37.5 | 40.6 | 43.7 | 37.5 | 43.7 | 46.8 | 56.2 | 65.6 | 56.2 | 65.6 |
| All (n = 196)b | Any | 48 (24.5%) | 28 (58.3%);3.7 [2-5.5] | 21 (43.7%);2.1[1-2.5] | 47.9 | 41.7 | 52.1 | 54.2 | 41.7 | 47.9 | 56.3 | 62.5 | 66.7 | 62.5 | 66.7 |
aAvailable resistance data;
bUnknown LPV/r use in 3 patients; PI, protease inhibitor; PR, protease; DRM, Drug resistance mutation; r, ritonavir used for boosting; ATV/r, boosted-atazanavir; DRV/r, boosted-darunavir; FPV/r, boosted-fosamprenavir; IDV/r, boosted-indinavir; LPV/r, boosted-lopinavir; NFV, nelfinavir; SQV/r, boosted-saquinavir; TVR/r, boosted-tipranavir; RT, retrotrancriptase; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-NRTI; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, estavudine; DDI, didanosine; FTC, emtricitabine; TDF, tenofovir; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine; cART, combination antiretroviral therapy; IQR, interquartile range.